Reverse splits in sub-$10M microcaps often face selling pressure post-split as the stock re-approaches the bid-price threshold. Monitor trading volume and price action around May 21; if the stock fails to hold above $1.00, delisting risk remains acute. No fundamental catalyst — avoid chasing the split-driven re-rate.
Price Chart
Executive Summary
Clearmind Medicine announced a 1-for-10 reverse share split effective May 21, 2026, intended to regain compliance with Nasdaq's minimum bid price rule. The filing confirms an existing risk and does not alter the company's financial trajectory or operating outlook.
Key Facts
- Reverse share split ratio: 1-for-10, effective May 21, 2026.
- Outstanding shares will be reduced from 10,190,337 to approximately 1,019,033.
- No fractional shares issued; fractional shares rounded up.
- Authorized share capital remains unchanged.
- Split approved by board on March 18, 2026.
- Company was already flagged for non-compliance; reverse split is a standard corrective action.
Financial Impact
No financial impact from the reverse split itself; share count adjusts mechanically, market cap unaffected. Company remains a $1M market cap clinical-stage biotech with no revenue reported in the filing.
Risk Factors
- Nasdaq delisting risk if bid price fails to remain above $1.00 after split.
- Post-split selling pressure typical for distressed microcap reverse splits.
- Company still pre-revenue and clinical-stage; no new financing or pipeline updates in this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-058701 |
| Document: ea029126901ex99-1.htm | 0001213900-26-058701 |
| Document: 0001213900-26-058701-index-headers.html | 0001213900-26-058701 |
| Document: 0001213900-26-058701-index.html | 0001213900-26-058701 |
| Document: 0001213900-26-058701.txt | 0001213900-26-058701 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | 6-K | $6.00 | awaiting T+60 | — | $5.87 (+2.17%) |
Oct 13, 2026 13d ago | 6-K | $6.23 | awaiting T+60 | — | $5.87 (−5.78%) |
Oct 8, 2026 18d ago | 6-K | $6.60 | awaiting T+60 | — | $5.87 (−11.06%) |
Oct 7, 2026 19d ago | 6-K | $6.60 | awaiting T+60 | — | $5.87 (−11.06%) |
Sep 23, 2026 4w ago | 6-K | $0.8500 | awaiting T+60 | — | $5.87 (+590.59%) |
Sep 23, 2026 4w ago | Press Release | $0.8500 | awaiting T+60 | — | $5.87 (+590.59%) |
Sep 17, 2026 5w ago | Press Release | $6.86 | awaiting T+60 | — | $5.87 (−14.48%) |
Sep 14, 2026 6w ago | 6-K | $0.9440 | awaiting T+60 | — | $5.87 (+521.82%) |
Sep 8, 2026 6w ago | 6-K | $1.03 | awaiting T+60 | — | $5.87 (+469.90%) |
Sep 4, 2026 7w ago | 6-K | $1.16 | awaiting T+60 | — | $5.87 (−406.03%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers